FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
update
/
details

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

NextEdge Admin

29 Nov 2024

1 min 53 sec

BioArctic AB’s partner, Eisai, has announced the launch of Leqembi® (lecanemab) in South Korea following its approval in May 2024. The treatment targets adults with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD) dementia, collectively termed early AD. Eisai estimates that in 2021, South Korea had approximately 900,000 dementia patients, with one in ten individuals over 65 affected. Alzheimer’s accounts for 70% of all dementia cases, with one in five seniors experiencing MCI.

Leqembi is the first approved therapy to slow cognitive and functional decline by selectively binding to amyloid-beta (Aβ) aggregates, including protofibrils and insoluble plaques, key components in AD. By reducing Aβ protofibrils and plaques in the brain, Leqembi effectively addresses disease progression.

This breakthrough drug is the product of a long-standing collaboration between BioArctic and Eisai, based on research by Professor Lars Lannfelt and the discovery of the Arctic mutation in Alzheimer’s disease. Eisai manages clinical development, market approval, and global commercialization, while BioArctic retains joint commercialization rights in the Nordic region, pending European approval. Initially, Leqembi will be available on South Korea’s private market. Preparations are underway for a Nordic launch upon regulatory clearance.